Intech Investment Management LLC Sells 4,309 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Intech Investment Management LLC lowered its stake in United Therapeutics Co. (NASDAQ:UTHR) by 22.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,103 shares of the biotechnology company’s stock after selling 4,309 shares during the period. Intech Investment Management LLC’s holdings in United Therapeutics were worth $4,811,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. ClariVest Asset Management LLC increased its position in shares of United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 42 shares during the period. V Square Quantitative Management LLC bought a new stake in United Therapeutics during the 2nd quarter valued at approximately $30,000. Innealta Capital LLC bought a new stake in United Therapeutics during the 2nd quarter valued at approximately $33,000. Rise Advisors LLC purchased a new position in shares of United Therapeutics during the 1st quarter worth approximately $32,000. Finally, Benjamin F. Edwards & Company Inc. raised its position in shares of United Therapeutics by 63.6% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 117 shares in the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

UTHR has been the topic of several recent research reports. LADENBURG THALM/SH SH cut United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. UBS Group upped their target price on shares of United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research report on Monday, July 8th. Oppenheimer lifted their price target on shares of United Therapeutics from $400.00 to $575.00 and gave the company an “outperform” rating in a research report on Wednesday, August 28th. TD Cowen upped their price objective on shares of United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. Finally, StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, August 2nd. One analyst has rated the stock with a sell rating, three have issued a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $350.36.

Insider Activity

In other United Therapeutics news, Director Nilda Mesa sold 266 shares of United Therapeutics stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $318.58, for a total value of $84,742.28. Following the completion of the sale, the director now owns 5,107 shares of the company’s stock, valued at approximately $1,626,988.06. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other United Therapeutics news, Director Nilda Mesa sold 266 shares of the firm’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $318.58, for a total value of $84,742.28. Following the transaction, the director now directly owns 5,107 shares of the company’s stock, valued at $1,626,988.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 269 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $348.41, for a total value of $93,722.29. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $45,293.30. The disclosure for this sale can be found here. Insiders sold 110,922 shares of company stock valued at $36,541,398 over the last three months. Insiders own 12.50% of the company’s stock.

United Therapeutics Stock Performance

Shares of UTHR opened at $353.00 on Friday. The company has a market cap of $15.66 billion, a price-to-earnings ratio of 16.69, a P/E/G ratio of 1.25 and a beta of 0.57. The business’s fifty day simple moving average is $339.19 and its two-hundred day simple moving average is $291.68. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $366.08. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing the consensus estimate of $6.33 by ($0.48). The business had revenue of $714.90 million during the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. United Therapeutics’s quarterly revenue was up 19.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.24 earnings per share. Research analysts anticipate that United Therapeutics Co. will post 24.86 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.